Calcium–phosphate metabolism in patients with multiple sclerosis

Abstract

Introduction and objectivesThe purpose of this study was to evaluate the concentration of 25-hydroxycholecalciferol and parameters of calcium–phosphate metabolism at different periods of relapsing–remitting multiple sclerosis (RRMS).Materials and methodsForty-five patients, residents of Poland (49°–50°, N), were enrolled in the study, i.e. 15 immediately after the diagnosis of RRMS, 15 at the early stage and 15 at the advanced stage of RRMS. The results were compared to values obtained in 20 age- and sex-matched controls.ResultsLower serum concentrations of 25-hydroxycholecalciferol and ionised calcium were found in patients compared to the control group. In patients with the disease duration of 5–6 years, concentrations of 25-hydroxycholecalciferol and ionised calcium were lower than in patients in the earlier period of RRMS. The inverse and clearer direction of changes was found in parathormone serum concentration in patients compared to the controls. In patients with a longer disease duration, a significantly lower 25-hydroxycholecalciferol concentration was found in female patients compared to male patients. In patients, more frequent 25-hydroxycholecalciferol and unsaturated fatty acids’ supplementation was observed compared to the controls.ConclusionsIn RRMS patients, calcium–phosphate metabolism is disturbed which increases during disease progression.

Assessment of Biochemical and Densitometric Markers of Calcium-Phosphate Metabolism in the Groups of Patients with Multiple Sclerosis Selected due to the Serum Level of Vitamin D3

“…In turn, the determination of levels of albumins and total protein which has an impact on the active fraction of total calcium could have modified the results. The lack of differences in the levels of ALP between VitDd, VitDi, and VitDn is consistent with the study conducted in patients who did not use DMT [ 22 ].…”

Salivary profile and dental status of patients with multiple sclerosis

“…24 According to Kubicka-Baczyk et al, the MS patients had a significantly higher level of serum parathormone than the controls. 25 In their study, daily urine calcium excretion was lower in the patients than in the healthy controls; the serum phosphorus, calcium and alkaline phosphatase levels were higher in the patients than in the controls, but these differences were not statistically significant. 25 In contrast to all the aforementioned studies, Chałas found that the calcium levels in the saliva of the MS patients were significantly lower than in the healthy controls.…”

“…25 In their study, daily urine calcium excretion was lower in the patients than in the healthy controls; the serum phosphorus, calcium and alkaline phosphatase levels were higher in the patients than in the controls, but these differences were not statistically significant. 25 In contrast to all the aforementioned studies, Chałas found that the calcium levels in the saliva of the MS patients were significantly lower than in the healthy controls. 3 This difference may be related to different patient characteristics, such as the duration of the disease, the type of medications taken, study sample size, the methods of calcium detection, and different inclusion and exclusion criteria according to the study design.…”

Metastatic calcinosis cutis due to refractory hypercalcaemia responsive to denosumab in a patient with multiple sclerosis

“…Metastatic calcinosis cutis is a rare but potentially devastating consequence of hypercalcaemia. On the other hand, in patients suffering from multiple sclerosis (MS), low calcium and vitamin D levels have been shown to correlate with MS relapses, decreased anti-inflammatory effects and immunomodulation 1–4. It is thus common practice among neurologists to recommend additional sources of vitamin D and calcium for this population 5 6.…”